Oxaliplatin-induced immune mediated thrombocytopenia

Muhammad S. Beg; Rami S. Komrokji; Kashif Ahmed; Malek M. Safa

doi:10.1007/s00280-007-0675-5

Oxaliplatin-induced immune mediated thrombocytopenia

Muhammad S. Beg, Rami S. Komrokji, Kashif Ahmed, Malek M. Safa

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Original language	English (US)
Pages (from-to)	925-927
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	62
Issue number	5
DOIs	https://doi.org/10.1007/s00280-007-0675-5
State	Published - Oct 2008

Keywords

Immune
Oxaliplatin
Thrombocytopenia

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s00280-007-0675-5

Cite this

@article{4377c55190ab49cbaf4589207a53e547,

title = "Oxaliplatin-induced immune mediated thrombocytopenia",

abstract = "Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.",

keywords = "Immune, Oxaliplatin, Thrombocytopenia",

author = "Beg, {Muhammad S.} and Komrokji, {Rami S.} and Kashif Ahmed and Safa, {Malek M.}",

year = "2008",

month = oct,

doi = "10.1007/s00280-007-0675-5",

language = "English (US)",

volume = "62",

pages = "925--927",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - Oxaliplatin-induced immune mediated thrombocytopenia

AU - Beg, Muhammad S.

AU - Komrokji, Rami S.

AU - Ahmed, Kashif

AU - Safa, Malek M.

PY - 2008/10

Y1 - 2008/10

N2 - Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

AB - Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

KW - Immune

KW - Oxaliplatin

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=49749126792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749126792&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0675-5

DO - 10.1007/s00280-007-0675-5

M3 - Article

C2 - 18204841

AN - SCOPUS:49749126792

SN - 0344-5704

VL - 62

SP - 925

EP - 927

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

Oxaliplatin-induced immune mediated thrombocytopenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this